Supriya Lifescience Ltd
Supriya Lifescience Ltd (SUPRIYA) last traded at ₹795, a market capitalisation of ₹6,396 crore, on a P/E of 32.2. Over the past 52 weeks the stock has ranged between ₹546 and ₹1,086. Supriya Lifescience Ltd last reported results for the quarter ended Jun 2026, with sales of ₹190 crore and net profit of ₹24 crore. Figures are as of 25 Aug 2026 and are not real time.
Supriya Lifescience Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Supriya Lifescience Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹190 cr, up 31.0% from ₹145 cr a year earlier. Net profit was ₹24 cr, down 31.4% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 166 | 186 | 184 | 145 | 200 | 206 | 277 | 190 |
| Expenses | 101 | 120 | 117 | 93 | 127 | 134 | 179 | 142 |
| Operating profit | 65 | 66 | 68 | 52 | 73 | 72 | 98 | 47 |
| OPM % | 39% | 36% | 37% | 36% | 36% | 35% | 35% | 25% |
| Other income | 3 | 2 | 3 | 3 | 3 | 2 | 3 | 3 |
| Interest | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 9 |
| Profit before tax | 62 | 63 | 64 | 47 | 68 | 67 | 92 | 41 |
| Tax % | 26% | 25% | 21% | 27% | 26% | 26% | 19% | 41% |
| Net profit | 46 | 47 | 50 | 35 | 50 | 50 | 74 | 24 |
| EPS (₹) | 5.73 | 5.81 | 6.26 | 4.32 | 6.27 | 6.17 | 9.22 | 2.99 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Supriya Lifescience Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 391 | 530 | 461 | 570 | 696 | 828 | 873 |
| Operating profit | 173 | 214 | 129 | 176 | 261 | 294 | 290 |
| OPM % | 44% | 40% | 28% | 31% | 37% | 36% | 33% |
| Net profit | 124 | 152 | 90 | 119 | 188 | 209 | 198 |
| EPS (₹) | 16.89 | 18.86 | 11.17 | 14.80 | 23.35 | 25.98 | 24.65 |
TTM is the trailing twelve months to the most recent quarter.
Supriya Lifescience Ltd growth and returns
- 10 Years
- %
- 5 Years
- 16%
- 3 Years
- 22%
- TTM
- 28%
- 10 Years
- %
- 5 Years
- 11%
- 3 Years
- 33%
- TTM
- 12%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 44%
- 1 Year
- 20%
- 10 Years
- 23%
- 5 Years
- 20%
- 3 Years
- 19%
- Last Year
- 19%
Supriya Lifescience Ltd shareholding pattern
Promoters held 68.30% at Jun 2026, broadly unchanged since Jun 2025. FIIs 6.18% and DIIs 5.30%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% |
| FIIs | 6.03% | 6.52% | 7.19% | 6.78% | 5.46% | 5.19% | 5.16% | 6.18% |
| DIIs | 5.45% | 4.93% | 4.26% | 4.86% | 5.22% | 5.00% | 5.70% | 5.30% |
| Public | 20.22% | 20.25% | 20.25% | 20.08% | 21.02% | 21.49% | 20.83% | 20.21% |
| No. of shareholders | 85,328 | 89,394 | 91,051 | 91,928 | 87,912 | 85,099 | 81,161 | 82,082 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Supriya Lifescience Ltd corporate filings
- Voting Results and Scrutinizer''s Report for the Postal ballot conducted by the Company are enclosed herewith.AGM/EGMlow impact
Cruxal's analysis: Supriya Lifescience Limited has confirmed the re-appointment of Mr. Balasaheb Sawant as…
Read the full analysis - Earnings Call Transcript of the Earning Call for Unaudited Financial Results for quarter ended June 30, 2026 is enclosed.Company Updatemedium impact
Cruxal's analysis: Supriya Lifescience reported Q1 FY27 revenue of 190 crore, a 31% YoY growth, despite…
Read the full analysis - Audio Link for outcome of Results Earnings Call for United Financial Results for quarter ended June 30, 2026 is enclosed.Company Updatelow impact
Cruxal's analysis: Supriya Lifescience Limited has formally uploaded the audio recording of its earnings…
Read the full analysis - Enclosed herewith Copy of Newspaper Publication of Results for quarter ended June 30, 2026.Company Updatehigh impact
Cruxal's analysis: Supriya Lifescience Limited reported Q1 FY27 standalone revenue of 189.75 crore…
Read the full analysis - Press Release for Unaudited Financial Results for quarter ended June 30, 2026 is enclosed herewith.Company Updatehigh impact
Cruxal's analysis: Supriya Lifescience reported Q1 FY27 revenue of 189.75 crore, a 31% YoY increase, driven…
Read the full analysis - Investor Presentation for Results Earnings Call for Unaudited Financial Results for quarter ended June 30,2026 is enclosed herewith.Company Updatehigh impact
Cruxal's analysis: Supriya Lifescience reported Q1 FY27 revenue of 189.75 crore, reflecting a 31% YoY…
Read the full analysis - Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held ....Board Meetinghigh impact
Cruxal's analysis: Supriya Lifescience reported Q1 FY27 standalone revenue of 189.75 crore, reflecting a…
Read the full analysis - Intimation of the Earnings call for Unaudited Financial Results of the Company for the quarter ended June 30, 2026 is enclosed herewith.Company Updatelow impact
Cruxal's analysis: Supriya Lifescience Ltd has announced an earnings conference call to discuss its…
Read the full analysis - Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve In terms of Regulation ....Board Meetinglow impact
Cruxal's analysis: Supriya Lifescience Limited has formally intimated the stock exchanges regarding a Board…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Supriya Lifescience Ltd
Cruxal reads every Supriya Lifescience Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.